Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of HyQvia (TAK-771) in Japanese participants with primary immunodeficiency diseases
2022-003622-45Phase 3
- Sponsor
- Takeda
- Start
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Human normal immunoglobulin G in Immunogenetic disorder, sponsored by Takeda. Primary endpoint: Epoch 2: Serum trough levels of total IgG antibodies after administration of TAK-771.
02
Drugs
Human normal immunoglobulin G
03
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on 2022-003622-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003622-45.